Table 1 Baseline characteristics of this cohort

Gender, male, n (%)

61(85.9%)

15(93.8)

46(83.6)

0.309

Age, years

49.4 ± 12.9

46.6 ± 11.2

50.2 ± 13.4

0.323

BSA (m²)

1.85 ± 0.18

1.84 ± 0.17

1.85 ± 0.18

0.917

BMI (kg/m²)

26.0 ± 3.3

26.7 ± 2.5

25.8 ± 3.5

0.359

Systolic blood pressure (mmHg)

121 ± 14

118 ± 13

121 ± 15

0.429

Diastolic blood pressure (mmHg)

80 ± 9

78 ± 8

80 ± 9

0.375

Family history of HCM, n (%)

13(18.3)

3(18.8)

10(18.2)

0.959

Family relatives history of HCM, n (%)

18(25.4)

5(31.2)

13(23.6)

0.541

Family history of SCD, n (%)

6(8.5)

1(6.3)

5(9.1)

0.721

NYHA functions

 I, n (%)

69

14

46

 II, n (%)

2

2

0

0.008

 ≥ III, n (%)

0

0

0

 Symptoms (%)

18(25.4)

14(87.5)

4(7.2)

 < 0.001

 Chest tightness, n (%)

13

10

3(5.5)

 Chest pain, n (%)

1

1

0

 Palpitation, n (%)

4

3

1(1.8)

Echocardiography

 Apical HCM, n (%)

3(4.2)

3(18.8)

0

0.001

 Suspicious apical HCM, n (%)

8(11.3)

7(43.8) ^*

1(1.8)

 < 0.001

Electrocardiography

 Giant negative T waves, n (%)

71(100)

16(100)

55(100)

1.000

 ST-T abnormality, n (%)

15(21.1)

13(81.3)^*

2(3.6)

 < 0.001

 LV hypertrophy, n (%)

10(14.1)

9(56.3) ^*

1(1.8)

 < 0.001

 Interval (mo) between CMRs

24.4 ± 8.3

33.9 ± 6.4^*

24.8 ± 5.7

 < 0.001

 Medications

25

15

10

 < 0.001

 Beta blocker, n (%)

18

10

8

 Calcium channel blocker, n (%)

3

2

1

 Others, n (%)

4

3

1